Neuropeptide S (human)

Research use only, not for human use.

Potent endogenous neuropeptide S receptor agonist (EC50 = 9.4 nM). Increases locomotor activity and wakefulness in mice. Also reduces anxiety-like behavior in mice.

Potent endogenous neuropeptide S receptor agonist (EC50 = 9.4 nM). Increases locomotor activity and wakefulness in mice. Also reduces anxiety-like behavior in mice.

Half-maximal effective concentrations (EC50) for mobilization of [Ca2+]i are 9.4 nM, 3.2 nM, and 3.0 nM for human, rat, and mouse Neuropeptide S (NPS), respectively.Neuropeptide S human (4 pM to 1.7 nM; 48 hours) retains full agonist activity with an EC50 of6.7 nM, the binding of [125I] Y10-hNPS to CHO cells stably expressing hNPSR is saturable with high affinity (Kd = 0.33 nM).Neuropeptide S human (1 pM-3 μM; 48 hours) are used to compete with 0.15 nM [125II] Y10-NPS,[125II] Y10-NPS is displaceable by increasing concentrations of human NPS (IC50 = 0.42 nM).

Neuropeptide S human (0.1 nM-1 nM; i.c.v.) causes a significant increase in locomotor activity, the total distance traveled, percentage of time moving, number of rearing events, and center entries are also significantly increased in mice. Animal Model:Male C57Bl/6 mice Dosage:0.1 nM, 1 nM Administration:Intracerebroventricular (i.c.v.) injectionResult:Increased locomotor activity and promoted wakefulness.

——

Others

Other Targets

——

——

——

412938-67-1

2187.5

C93H155N31O28S

>98% (HPLC)

water:1 mg/mL

[H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years